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Abstract: 
Successful delivery of promising new chemical entities via the oral route is rife with challenges, 
some of which cannot be explained or foreseen during drug development. Further complicating 
an already multifaceted problem is the obvious, yet often overlooked, effect of dietary substances 
on drug disposition and response. Some dietary substances, particularly fruit juices, have been 
shown to inhibit biochemical processes in the intestine, leading to altered pharmacokinetic (PK), 
and potentially pharmacodynamic (PD), outcomes. Inhibition of intestinal CYP3A-mediated 
metabolism is the major mechanism by which fruit juices, including grapefruit juice, enhances 
systemic exposure to new and already marketed drugs. Inhibition of intestinal non-CYP3A 
enzymes and apically-located transport proteins represent recently identified mechanisms that 
can alter PK and PD. Several fruit juices have been shown to inhibit these processes in vitro, but 
some interactions have not translated to the clinic. The lack of in vitro-in vivo concordance is due 
largely to a lack of rigorous methods to elucidate causative ingredients prior to clinical testing. 
Identification of specific components and underlying mechanisms is challenging, as dietary 
substances frequently contain multiple, often unknown, bioactive ingredients that vary in 
composition and bioactivity. A translational research approach, combining expertise from 
clinical pharmacologists and natural products chemists, is needed to develop robust models 
describing PK/PD relationships between a given dietary substance and drug of interest. 
Validation of these models through well-designed clinical trials would facilitate development of 
common practice guidelines for managing drug-dietary substance interactions appropriately. 
 
Article: 
INTRODUCTION 
Interpatient differences in response to therapeutic agents represent one of the most challenging 
complications in clinical practice. Such complications can delay, even prevent, optimal treatment 
outcomes, which can negatively impact quality of life and health care costs. Genetic, 
pathophysiologic, and environmental factors all contribute to variation in drug response, which is 
in part due to large interindividual differences in processing xenobiotics via absorption, 
distribution, and elimination. Significant resources continue to be invested in delineating genetic 
factors associated with variation in drug disposition, and in turn drug response, with the promise 
of “personalized medicine” [1-3]. Comparatively less attention has been directed toward non-
genetic factors, which are equally important in determining drug response [4], and whose 
contribution increases with age [5]. Because ingestion of dietary substances, as foods or 
supplements, undoubtedly constitutes the largest portion of environmental exposure to 
xenobiotics, evaluation of the influence of dietary substances on drug disposition is prudent to 
improving the understanding of interindividual differences in response to therapeutic agents. 
 
Dietary substances perhaps have the greatest impact on drug disposition processes in the 
intestine, as most drugs and dietary substances enter the body by the oral route and are absorbed 
subsequently by enterocytes. Like hepatocytes, enterocytes express myriad metabolizing 
enzymes and transport proteins that influence, at least in part, the extent of systemic drug 
exposure [6, 7]. The clinical significance of the intestine as a contributor to drug disposition and 
as a site for drug-drug interactions (DDIs) is widely recognized. Incorporation of intestinal 
biochemical processes in DDI prediction models is the topic of several recent reviews and 
original research articles [8-15]. 
 
Although dietary substances are regulated as food, bioactive compounds in these substances can 
act like drugs. Presumed bioactive compounds often are extracted and sold as dietary or herbal 
supplements. The ever-increasing popularity of certain foods and dietary supplements as a means 
to decrease health care costs via self-diagnosis and treatment is due in part to the widely held 
view that these products are safer, “natural” alternatives to prescription, as well as non-
prescription, drugs [16, 17]. Evaluation of drug interaction liability of new drug candidates is 
strictly defined [18, 19], whereas that for foods and supplements is not. Consequently, robust 
guidelines on the evaluation of potential drug-dietary substance interactions are essentially non-
existent. Lack of guidance in this area has led to a multitude of studies that often are difficult to 
compare, inconclusive, and fail to meet strict definitions required to make informed clinical and 
regulatory decisions. The current review focuses on new findings and developments over the last 
two years in drug-dietary substance interaction research and addresses concerns regarding 
interpretation of associated studies. 
 
OVERVIEW OF DRUG-DIETARY SUBSTANCE INTERACTIONS 
A drug-dietary substance interaction is defined as the result of a physical, chemical, physiologic, 
or pathophysiologic relationship between a drug and a nutrient(s) present in a food, nutritional 
supplement, or food in general [20]. Such an interaction manifests clinically as compromised 
nutritional status due to addition of a drug or altered pharmacokinetics (PK) and/or 
pharmacodynamics (PD) of a drug or dietary substance. Like drugs, dietary substances can act as 
objects or precipitants [21], the latter of which can increase systemic drug exposure, augmenting 
the risk of adverse events and toxicity, or decrease systemic drug exposure, leading to 
therapeutic failure. These interactions are challenging to assess because, unlike most drug 
products, dietary substances are mixtures, composed of multiple, and usually unknown, bioactive 
ingredients. A mechanistic understanding of the varied effects of dietary substances on drug 
disposition would form a basis for optimizing pharmacotherapy by minimizing potential 
unwanted effects. 
 
Clinical Considerations 
Dietary habits often are an overlooked topic of discussion during clinician visits, as well as 
during clinical trial design. The general lack of awareness of clinicians to identify and properly 
manage drug-dietary substance interactions may predispose patients to unfavorable outcomes. 
The risk of experiencing a significant event depends on several factors. While a drug-dietary 
substance interaction may occur in any patient, those with weakened physiologic function, such 
as the elderly, immunocompromised, and critically ill, are at the highest risk of experiencing 
untoward effects [22]. Management of these relatively unexplored interactions is a challenge in 
clinical practice. The clinician must identify short- and long-term consequences, determine the 
need for dosing and/or timing adjustments for the drug(s), and consider alternative treatment 
approaches [23]. Understanding underlying mechanisms of the interaction and causative 
bioactive compounds will facilitate making the most appropriate decision. However, prospective 
and systematic investigations on mechanisms and outcomes of many interactions are insufficient 
or lacking altogether. Clinical interaction studies often do not support in vitro observations [24]. 
These in vitro-in vivo discordances raise questions about how research is conducted and 
interpreted. Taken together, practical approaches in the management of these interactions are 
difficult to formulate. Development of common practice guidelines to provide a consistent and 
comprehensive recommendation on avoiding or assessing drug-dietary substance interactions can 
be achieved only by designing and conducting robust clinical studies. 
 
Dietary Substances as Precipitants of Altered Drug Exposure and Response 
Dietary substances as precipitants can alter drug absorption, distribution, and/or elimination via 
physicochemical and biochemical mechanisms. Physicochemical mechanisms include 
inactivation of the drug by the dietary substance. For example, enteral feeding formulas are 
physically incompatible with certain medications. The antiepileptic agent, phenytoin, can bind to 
proteins and salts in enteral formulations, resulting in reduced phenytoin absorption, reduced 
serum concentrations, and potentially, inadequate seizure control [25]. Some tetracyclines and 
fluoroquinolones can bind to divalent cations in dairy products (e.g., calcium), resulting in 
reduced drug absorption and potential therapeutic failure [26, 27]. Biochemical mechanisms 
include alterations of gastroenterologic processes, interference with co-factor formation or 
function, and modification of drug metabolizing enzyme/transporter function by the dietary 
substance. For example, high fat meals can increase drug absorption by improving solubility or 
stimulating gastrointestinal enzymes and bile flow [28]. The antifungal agent, griseofulvin, and 
antiviral agent, saquinavir, are recommended to be taken with such meals [29]. Food and 
beverages in general can delay gastric emptying or change gastric pH, causing reduced 
absorption of some drugs, including penicillins and proton pump inhibitors [30]. Vitamin K-rich 
foods, such as dark green leafy vegetables, are examples of dietary substances that interfere with 
co-factor function [31]. These foods should be consumed cautiously with the anticoagulant, 
warfarin, as they can interfere with vitamin K metabolism and increase risk of bleeding or clot 
formation [32]. Fruit juices are examples of dietary substances that modify drug 
metabolism/transport and are the focus of this review. Other examples of drug-dietary substance 
interactions are discussed comprehensively in several sources [33-36]. 
 
MECHANISMS OF ALTERED SYSTEMIC DRUG EXPOSURE VIA INHIBITION OF 
INTESTINAL BIOCHEMICAL PROCESSES 
The gastrointestinal tract is exposed continuously to a variety of xenobiotics, the majority of 
which are components of the diet. Fruit juices are touted frequently as healthy foods due to high 
antioxidant content, which is believed to slow onset of disease and aging [37]. These ubiquitous 
products are ready-made, easily obtained, and affordable. They have become highly 
recommended supplements to routinely prescribed and over-the-counter drugs and/or 
monotherapy for prevention, treatment, and maintenance of common diseases (e.g., 
hypercholesterolemia, hypertension, and diabetes mellitus). The prevalence of these chronic 
conditions, and associated use of medications and fruit juices, is expected to rise [38-40]. 
 
Compared to drugs, less attention has been given to the possibility that dietary substances can 
influence drug disposition via modulation of drug metabolizing enzymes and transporters. Fruit 
juices have been shown to inhibit metabolism and active apical efflux/uptake processes in the 
intestine [41]. Inhibition of metabolism and active efflux would be expected to increase, whereas 
inhibition of active uptake would be expected to decrease, systemic drug exposure. These 
biochemical mechanisms of the intestine are highlighted in the current review. 
 
Cytochrome P450 3A 
Cytochrome P450 (CYP) enzymes constitute the major catalysts of phase I drug 
biotransformation [42]. The CYP3A subfamily, consisting primarily of CYP3A4 and CYP3A5, 
is the most abundantly expressed in the intestine, representing, on average, approximately 80% 
of total immunoquantified CYP protein [43]. CYP3A is believed to be involved in the oxidative 
metabolism of over 50% of pharmaceutical agents [44]. Some fruit juices have been shown to 
inhibit enteric CYP3A, leading to clinical consequences [45]. Although several in vitro 
observations have translated to the clinic, generalizations about the effect of fruit juices on the 
metabolism of CYP3A substrates should be avoided since the effect may be substrate-dependent. 
 
Grapefruit Juice. The grapefruit (Citrus × paradisi), particularly as juice, is one of the most 
extensively studied dietary substances shown to interact with an array of medications [46]. 
Grapefruit juice (GFJ) can enhance systemic drug exposure, by up to 1400%, by inhibiting 
CYP3A-mediated pre-systemic (first-pass) metabolism in the intestine [47]. Inhibition is 
localized largely in the gut, as reflected by a lack of effect on the PK of an intravenously 
administered substrate and on the elimination half-life of an orally administered substrate [48]. 
The increase in systemic drug exposure can be sufficiently large to produce untoward effects, 
including muscle pain with some HMG CoA reductase inhibitors (statins) and severe 
hypotension with some calcium channel antagonists [49]. Accordingly, the package insert of 
more than 40 drugs, encompassing a range of therapeutic classes, carries a warning to avoid 
concomitant GFJ intake. 
 
The serendipitous observation of a PK/PD interaction between GFJ and the anti-hypertensive 
agent, felodipine [50], spurred numerous investigations of various drug-GFJ interactions. Modes 
of intestinal CYP3A inhibition by GFJ include reversible and mechanism-based [51], as well as 
destruction of the protein [52]. A number of causal ingredients were examined over a span of 15 
years before a class of compounds, furanocoumarins, was established as a major mediator of the 
‘GFJ effect’ in human subjects [53]. The discovery of the GFJ effect and subsequent 
investigations underscores the importance of the intestine as an organ of drug elimination and the 
possible importance of other dietary substances as modifiers of drug performance. Figure 1 
highlights other key observations since the discovery of the felodipine-GFJ interaction in 1989 
[54]. Table 1 summarizes the design and major results of recent healthy volunteer and patient 
studies reporting modest to significant PK interactions with medications that are CYP3A 
substrates. 
 
 
Figure 1: Timeline of key observations in drug-grapefruit juice (GFJ) interaction research. 
 
 
Table 1: Controlled clinical drug-grapefruit juice (GFJ) interaction studies reported since 2008 
Subjects 
(n) 
Drug Tested 
and Dosage 
GFJ Product (Manufacturer) 
and Administration Regimen 
Change 
in Mean AUC 
Reference 
 
Healthy 
volunteers 
(20) 
Itraconazole 
200 mg (20 mL oral 
solution) 
(day 3) 
Concentrate: diluted to single strength 
(Kroger Brand; The Kroger Co., 
Cincinnati, Ohio) 
240 mL tid × 2d 
200 mL × 2 (day 3) 
↑ 30% (women) 
(p = 0.01) 
 
↑ 11% (men) 
(p = 0.27) 
[62] 
Healthy 
volunteers 
(18) 
Cyclosporine 
5 mg/kg × 1 
Concentrate: diluted to single strength 
(NSP) 
 
FC-free: single strength* 
240 mL × 1 
↑ 38%§ 
(p < 0.01) 
 
↓ 1.8%§ 
(p > 0.70) 
[63] 
Healthy 
volunteers 
(19) 
Dextromethorphan 
10 mg (dissolved in 
50 mL water) × 1 
Concentrate: diluted to 0.25×, 0.5×, 
1×, 2× strength 
(Mainfrucht GmbH & Co. KG, 
Gochsheim, Germany) 
200 mL × 1 
↓ excretion of 
CYP3A- 
dependent 
metabolite 
(MOM) by 1× 
and 2× strength† 
(p < 0.05) 
[64] 
Healthy men 
(8) 
Budesonide 
3 mg (as ER) × 1 
(day 4) 
Freshly squeezed 
(AstraZeneca R&D, Lund, Sweden) 
200 mL tid × 3d 
200 mL × 1 (day 4) 
↑ 129% [65] 
Healthy 
volunteers 
(8) 
Sertraline 
75 mg × 1 (day 6) 
250 mL tid × 5d 
250 mL × 1 (day 6) 
↑ 51% 
(p = 0.002) 
[66] 
Liver transplant 
recipients 
(30, equally 
divided into 
groups A, B, 
and C) 
Tacrolimus 
NSP 
Concentrate: diluted to 0.125× 
strength 
(Guangdong Foshan Co., China) 
(group B) 
 
Single strength 
(Tianjin Chengbao Fresh Grapefruit 
Juice Co., China) (group C) 
 
250 mL bid × 1 week 
↑ 22% 
(p < 0.01) 
 
 
 
↑ 110% 
(p < 0.001) 
[67] 
 
 
 
Healthy men 
(21) 
Nilotinib 
400 mg × 1 
Concentrate: diluted to 2× strength 
(Kroger Brand; The Kroger Co., 
Cincinnati, Ohio) 
240 mL × 1 
 
↑ 29% 
(p = 0.004) 
[68] 
Cancer patients 
(8) 
Sunitinib 
25/37.5/50‡ mg qd 
(6-week treatment 
cycle: 4 weeks on, 2 
weeks off) 
NSP 
200 mL tid × 3d (day 25, 26, 27) 
↑ 11% 
(p < 0.05) 
[69] 
 
 
Healthy 
volunteers 
(12) 
Oxycodone 
10 mg × 1 (day 4) 
Single strength 
(Greippi Täysmehu; Valio Ltd., 
Helsinki, Finland) 
200 mL tid × 5d 
↑ 67% 
(p < 0.001) 
[70] 
Healthy 
volunteers 
(11) 
Aliskiren 
150 mg × (day 3) 
Normal strength 
(Valio Greippitäysmehu; Valio Ltd., 
Helsinki, Finland) 
200 mL tid × 5d 
↓ 81% 
(p < 0.001) 
[71] 
*Manufactured from concentrate 
§Median AUC 
†CYP3A- and CYP2D6-dependent metabolites measured in urine only 
‡Dose depends on type of cancer 
GFJ, grapefruit juice; AUC, area under the curve; FC, furanocoumarin; MOM, 3-methoxymorphinan; ER, extended release; tid, three times daily; 
d, days; NSP, not specified; bid, two times daily; qd, daily 
 
Pomelo Juice. The pomelo (Citrus maxima), or pummelo, is a large citrus fruit native to Asia 
and is consumed typically as the fresh fruit. The grapefruit is believed to be an accidental hybrid 
of the pomelo and sweet orange (Citrus sinensis) [72]. Accordingly, it is reasonable to expect 
furanocoumarins are present in pomelos. Indeed, juice prepared from some species of pomelo 
has been reported to contain furanocoumarins in concentrations comparable to those in GFJ [73]. 
Clinical interactions with tacrolimus [74] and cyclosporine [75] via enteric CYP3A inhibition, 
albeit modest, have been reported. A clinical study of pomelo juice evaluated the extent of 
inhibition based on the species of pomelo [76]. Freshly prepared juices from two varieties of fruit 
(‘Guanximiyou’ and ‘Changshanhuyou’) were given, on separate occasions, with felodipine (10 
mg) to 12 healthy volunteers. Each juice was measured for furanocoumarin content and tested 
for inhibition of CYP3A activity (testosterone 6β-hydroxylation) in human liver microsomes 
prior to clinical testing; at 2.5% juice (v/v), extents of inhibition were ~30% (Guanximiyou) and 
<5% (Changshanhuyou), relative to control. The more potent juice increased both mean area 
under the curve (AUC) and maximum concentration (Cmax) of felodipine, by ~40% (p<0.05), 
whereas the less potent juice increased these values by ~15% (NS) relative to water. Heart rate 
also was measured to determine effects on felodipine PD. Neither juice altered mean heart rate 
significantly. Unlike the tacrolimus and cyclosporine studies, the felodipine study acknowledged 
and attempted to account for PK variability with respect to furanocoumarin composition in the 
juice (see DISCORDANCE BETWEEN IN VITRO AND CLINICAL STUDIES). 
 
A clinical study of six healthy men showed a significant interaction between pomelo juice and 
sildenafil (50 mg), indicated for erectile dysfunction and pulmonary hypertension [77]. Since 
sildenafil undergoes extensive intestinal first-pass metabolism by CYP3A (oral bioavailability 
~40%), and pomelos contain furanocoumarins, an increase in systemic sildenafil exposure 
(relative to water) was expected. However, the juice significantly decreased mean AUC and Cmax 
of sildenafil. The authors speculated the mechanism was either a physicochemical interaction 
between sildenafil and components of the juice or inhibition of an intestinal uptake process (see 
Uptake Transport Proteins). Unlike the aforementioned study with felodipine, 
furanocoumarins were not measured in the juice. 
 
Cranberry Juice. The cranberry (Vaccinium macrocarpon) has long been considered a health 
food, touted for beneficial effects on diverse ailments [78]. More than 150 individual compounds 
have been identified [79]. As a rich source of phytochemicals, cranberries have shown anti-
atherosclerotic and anti-proliferative properties, which may be protective in cardiovascular 
disease and certain cancers [80]. Cranberry juice (CBJ) continues to maintain popularity, largely 
as prophylaxis and treatment for urinary tract infections (UTIs) [81]. An in vivo study in rats 
given CBJ and the CYP3A/Cyp3a substrate, nifedipine, indicated that the juice inhibited enteric 
Cyp3a activity to an extent comparable to that by GFJ [82]. A subsequent clinical study 
involving 12 healthy volunteers given cyclosporine and a single 240-mL glass of CBJ indicated 
no interaction [83]. However, use of cyclosporine as a CYP3A probe was not ideal since 
cyclosporine also is a substrate for the efflux transporter, P-glycoprotein (P-gp) (see Efflux 
Transport Proteins), and whether or not CBJ modulates intestinal P-gp activity is not known. 
 
Two clinical trials using midazolam as a CYP3A/non-P-gp probe showed conflicting results. The 
first study involved 10 healthy volunteers given a thrice daily regimen of a commercially 
available CBJ concentrate (diluted 1:4) for 10 days and a single dose of midazolam (0.5 mg on 
day 5) [84]. Relative to water, a change in midazolam PK was not detected. The second study 
involved 16 healthy volunteers given a single dose of midazolam (5 mg) and three 240-mL 
glasses of ‘double strength’ CBJ [85]. Prior to the clinical study, five brands of juice were tested 
in vitro to identify a product to test in vivo. The most potent brand selected increased geometric 
mean AUC of midazolam significantly, by ~30% relative to water, with no effect on elimination 
half-life. Another feature of the second study was that in vitro bioactivity-guided fractionation 
was utilized to isolate and identify candidate CYP3A inhibitors. The clinical test juice, a 
concentrate, was fractionated to generate hexane-, chloroform-, butanol-, and aqueous-soluble 
fractions. The hexane- and chloroform-soluble fractions (50 μg/mL) inhibited CYP3A activity 
(midazolam 1′-hydroxylation) in human intestinal microsomes by ~80 and 60%, respectively, 
suggesting the CYP3A inhibitors resided in these more lipophilic fractions. The juice was 
purified further until three triterpenes were isolated (maslinic acid, corosolic acid, ursolic acid) 
as candidate causative ingredients, with IC50 values ≤10 μM) [86]. The discrepancy between the 
two clinical studies may be explained by the difference in concentration of bioactive 
components. Only one brand was tested in the first study [84], and various components 
(anthocyanins, flavonols, hydroxycinnamic acids, hydroxybenzoic acids, and catechins) were 
measured. The most abundant was the flavonol, rutin, but CYP3A inhibition potency was not 
evaluated in vitro. Recognizing the substantial variability of bioactive components in natural 
products, the second study [85] began with in vitro testing to inform selection of the most 
appropriate brand for clinical testing and to generate candidate enteric CYP3A inhibitors for 
further investigation. 
 
Although not intestinal CYP3A metabolism-based, the presumed warfarin-CBJ interaction via 
inhibition of hepatic CYP2C9 continues to be a topic of debate. Case reports persist despite 
randomized clinical trials in healthy volunteers and stably anticoagulated patients demonstrating 
no evidence of a PK/PD interaction. One exception is a three-arm, randomized crossover study 
involving 12 healthy men given a single dose of warfarin (25 mg) alone or with a commercially 
available garlic or cranberry product, the latter a capsule formulation of a cranberry juice 
concentrate [87]. Subjects were treated with cranberry (or garlic) daily for three weeks. Warfarin 
was given after the second week. Warfarin PK and PD were assessed; PD were measured by the 
International Normalized Ratio (INR), platelet aggregation, and clotting factor activity. 
Compared to warfarin alone, cranberry increased area under the INR-time curve significantly, by 
30%, but had no effect on warfarin PK, platelet aggregation, and clotting factor activity. The 
increased area under the INR-time curve could have reflected the higher-than-average warfarin 
dose and/or “megadose” of cranberry, which was equivalent to 57 g of cranberry fruit daily and 
was more than triple the UTI prophylaxis “dose” recommendation [88]. A review published in 
2010 discussed studies to date (including the aforementioned sole finding) and concluded that 
moderate consumption of CBJ does not affect anticoagulation and that inclusion of precautionary 
warnings in warfarin product labeling should be re-examined [89]. Nevertheless, warfarin 
labeling continues to advise patients to avoid taking cranberry juice or cranberry products [90]. 
A more thorough understanding of the CBJ product in question is necessary to ascertain whether 
or not CBJ can enhance systemic exposure to clinically relevant CYP2C9, as well as CYP3A, 
substrates in humans. 
 
Pomegranate Juice. The pomegranate (Punica granatum) and associated by-products is one of 
the most popular superfoods on the market. Like CBJ, pomegranate juice is a complex mixture 
of polyphenolic compounds with high antioxidant potency [91]. Human in vitro and rat in vivo 
studies suggested that pomegranate juice can inhibit enteric CYP3A/Cyp3a activity 
(carbamazepine expoxidation) [92]. However, a subsequent clinical study involving 13 healthy 
men given 240 mL of pomegranate juice and a single oral dose of midazolam (6 mg) suggested 
minimal interaction, despite inhibition of CYP3A activity (triazolam hydroxylation) in human 
liver microsomes [93]. Likewise, another study involving 12 healthy subjects given a single dose 
of simvastatin (40 mg) after treatment with of a different brand of pomegranate juice (300 mL 
three times daily for three days) reported no interaction [94]. Generalizations about the enteric 
CYP3A inhibition potential of pomegranate juice are cautioned, as minimal to no information 
was provided about the test juices and their composition, precluding between-study comparisons. 
In addition, neither clinical study provided a sample size justification. 
 
Recent anecdotal reports have suggested an interaction between pomegranate juice and warfarin, 
as assessed by an increase in INR [95, 96]. Although hepatic CYP2C9/enteric Cyp2c inhibition 
by pomegranate juice has been demonstrated in human liver microsomes and rats with the probe 
substrates diclofenac and tolbutamide [97], respectively, no clinical trials have been reported. 
One case report involving rosuvastatin, which undergoes minimal metabolism, described 
rhabdomyolysis possibly due to an interaction with pomegranate juice [98]. This observation has 
yet to be investigated experimentally. 
 
Esterase 
Ester prodrugs are designed commonly to increase drug absorption [99]. Upon ester bond 
cleavage through hydrolysis or oxidation, active drug is released. Major esterases that hydrolyze 
prodrugs include carboxylesterase, acetylcholinesterase, butyrylcholinesterase, paraoxonase, and 
arylesterase [100]. Esterases are localized in multiple tissues, particularly blood, liver, and 
intestine [101]. Esterase inhibition could lead to increased stability of the ester in the lumen and 
enterocytes, resulting in higher absorption of the ester and higher exposure to active metabolite 
via rapid hydrolysis in plasma. 
 
Grapefruit Juice. Enalapril is a prodrug that is metabolized primarily by carboxylesterase to 
enalaprilat, an angiotensin converting enzyme inhibitor [102]. Lovastatin, indicated for 
hypercholesterolemia, is a prodrug that is hydrolyzed to the active acid by carboxylesterase, as 
well as oxidized to several inactive metabolites by CYP3A/Cyp3a; hydrolysis is considered the 
major metabolic pathway [103]. Lovastatin also has been suggested to be a weak substrate for P-
gp [104]. Effects on the apical-to-basolateral (absorptive) permeability and/or metabolism of 
enalapril and lovastatin by GFJ (diluted 1:3 from frozen concentrate) were evaluated in a human 
intestine-derived cell line (Caco-2) and human intestinal and liver S9 fractions [105]. Relative to 
0% (v/v) juice (buffer), the permeability of enalapril (5 μM) in Caco-2 cells increased 
significantly, by 30-133%, over the range of juice concentrations tested (6.25-50%). Cellular 
accumulation of enalapril at 1 h increased by 39-87%, respectively, while that of enalaprilat 
decreased by 12-32%. Enalapril hydrolysis in both S9 fractions was inhibited by <20% up to 
40% juice. The permeability of lovastatin (5 μM) increased in the presence of GFJ, by 40% and 
22% at 6.25% and 12.5% juice, respectively, then decreased at the higher juice strengths (25% 
and 50%), possibly due to binding of drug to GFJ pulp in the apical compartment. Cellular 
accumulation of lovastatin at 1 h decreased by 5-42%, and lovastatin acid formation decreased 
by 29-80%, over the range of juice concentrations tested (6.25-50%). Lovastatin hydrolysis was 
reduced by ~50% in human intestinal S9 fractions up to 40% juice. Collectively, these in vitro 
observations suggested that GFJ inhibited enteric esterase activity, leading to increased prodrug 
stability. 
 
When GFJ concentrate (diluted 1:3) was administered orally to rats, before intravenous 
administration of enalapril or lovastatin (2 mg/kg), clearance and half-life of both prodrugs were 
unchanged relative to water, indicating that GFJ had no effect on hepatic esterase/Cyp3a activity 
[105]. After oral administration of enalapril (10 mg/kg) with water or GFJ concentrate (diluted 
1:3, 1:2, and undiluted), mean AUC of enalaprilat was increased, by 65, 70, and 16%, 
respectively, relative to water; prodrug was not measured. The decreased exposure at the higher 
strength was attributed to binding of drug to GFJ pulp. These results were consistent with 
observations with the esterase inhibitor, bis-p-nitrophenylphosphate. After oral administration of 
lovastatin (10 mg/kg) with water or GFJ concentrate (diluted 1:3, 1:2, and undiluted), mean AUC 
of lovastatin acid was increased by 279, 157, and 170%, respectively, relative to water; prodrug 
was not measured. Since lovastatin is a substrate for CYP3A/Cyp3a, the contribution of esterase 
inhibition was differentiated by measuring Cyp3a- and esterase-mediated metabolites in portal 
vein-cannulated rats pre-treated with GFJ (diluted 1:3). Both Cyp3a and esterase inhibition by 
GFJ led to similar increases in exposure to lovastatin and the active acid, as well as unchanged 
CYP3A-mediated metabolites, suggesting equal contribution by Cyp3a and esterase to the 
interaction. Taken together, these in vivo observations were consistent with enteric esterase 
inhibition by GFJ, leading to increased prodrug stability in enterocytes and higher exposure to 
active metabolite via hydrolysis in plasma. 
 
A follow-up in vitro study by the same investigators examined the esterase inhibition potential of 
10 GFJ components toward p-nitrophenylacetate (PNPA) hydrolysis in human liver microsomes 
[106]. The flavonoids kaempferol, quercetin, and naringenin showed potent inhibition of PNPA 
hydrolysis, with IC50 values of 62, 43, and 30 μM, respectively. The effect of kaempferol and 
naringenin on esterase-mediated hydrolysis of enalapril and lovastatin also were evaluated in 
Caco-2 cells and in rats. Compared to control (buffer), the absorptive permeability coefficient of 
enalapril (20 μM) in Caco-2 cells was increased with kaempferol and naringenin (each at 250 
μM) by 80% and ~200%, respectively, whereas that of lovastatin (20 μM) was increased by 
~65% with both flavonoids. Intracellular concentrations of enalaprilat and lovastatin acid 
decreased by ~60% and 46-70%, respectively, consistent with inhibition of esterase activity. Oral 
administration of enalapril and lovastatin (both at 10 mg/kg) with naringenin (10 mg/kg) to rats 
increased active metabolite AUCs significantly, by 38% and 288%, respectively, relative to 
water. Similarly, oral administration with kaempferol (10 mg/kg) increased metabolite AUCs by 
109 and 246%, respectively. Finally, in portal vein-cannulated rats, kaempferol (10 mg/kg) 
increased portal plasma exposure to lovastatin and lovastatin acid by 154% and 113%, 
respectively. Collectively, these observations suggested some flavonoids as potential candidate 
enteric esterase inhibitors in GFJ. However, more studies are needed to determine the clinical 
utility, as well as other causative ingredients, of this new type of drug-GFJ interaction. 
 
Sulfotransferase 
Conjugative enzymes generally increase hydrophilicity, facilitating elimination of endogenous 
substrates and xenobiotics [107]. Sulfotransferases (SULTs) catalyze the conjugation of 3′-
phosphoadenosine 5′-phosphosulfate with a number of endogenous low molecular weight 
compounds (e.g., steroids, catecholamines) and xenobiotics [108]. Three human SULT 
subfamilies have been identified, with at least 13 distinct members distributed in liver, brain, 
intestine, lung, kidney, and other tissues [109]. Some fruit juices have been shown to inhibit two 
members of the SULT1 family in vitro: SULT1A1 and SULT1A3, the latter of which is 
expressed only in extrahepatic tissues, including the intestine. 
 
Grapefruit Juice. SULT1A1 and SULT1A3 inactivate β2-adrenergic agonists in the liver and 
intestine, respectively [110]. The bronchodilators albuterol and terbutaline undergo extensive 
first-pass metabolism in both organs to sulfate conjugates [111]. An in vitro study using human 
recombinant SULT1A1 and SULT1A3 investigated the inhibitory effects of GFJ, orange juice, 
and various teas on SULT activity, as measured by p-nitrophenol and dopamine sulfation for 
SULT1A1 and SULT1A3, respectively [112]. GFJ, at a concentration of 10% (v/v), inhibited 
SULT1A1 and SULT1A3 by >90% and 50%, respectively, relative to control. Specific juice 
components also were tested and included naringin, naringenin, quercetin, bergamottin, and 6′,7′-
dihydroxybergamottin. Quercetin was the most potent, inhibiting by >90% (SULT1A1) and 50% 
(SULTA3), at a concentration of 10 μM. 
 
Orange Juice. Orange juice was tested in the same manner as GFJ in the aforementioned in vitro 
study [112]. As observed with GFJ, orange juice (10%, v/v) inhibited both SULTs, by >95% 
(SULT1A1) and 20% (SULT1A3). The orange juice components, tangeretin and nobiletin (both 
at 10 μM), were the most potent single components, inhibiting SULT1A1 almost completely and 
SULT1A3 by ~20%. As with GFJ, whether or not these observations translate to the clinic merits 
further investigation. 
 
Pomegranate Juice. The effect of pomegranate juice on sulfoconjugation was evaluated in 
Caco-2 cells [113]. The extent of inhibition of 1-naphthol sulfation by pomegranate juice was 
both concentration- and cell culture time-dependent. At the highest concentration tested (5%, 
v/v), the juice had no effect on SULT1A1 and SULT1A3 expression for up to 24 hours. 
Punicalagin, the most abundant polyphenol in pomegranate juice, was isolated and shown to 
inhibit sulfoconjugation in the cells, with an IC50 of 45 μM. Clinical significance of these in vitro 
observations has not been reported. 
 
Efflux Transport Proteins 
The influence of efflux transporters is considered integral to drug disposition [114]. Similar to 
inhibition of enzymes, inhibition of efflux transporters can lead to altered systemic and local 
drug concentrations. The most well-characterized efflux transporter, P-gp, shares tissue 
distribution and substrate specificity with many CYPs, especially CYP3A [115]. Due to the 
apical (lumenal) location on membranes of enterocytes, P-gp functions to extrude substrates back 
into the intestinal lumen, lowering systemic drug concentrations. Thus, as with enteric CYP3A, 
inhibition of enteric P-gp would be expected to enhance systemic drug exposure. 
 
Grapefruit Juice. Whether or not GFJ modulates intestinal P-gp activity remains controversial 
[110]. One reason for the inconsistency is use of P-gp substrates that also are CYP3A substrates 
[116]. The contribution by P-gp and CYP3A is difficult to distinguish. Cyclosporine, a 
commonly used immunosuppressant with a narrow therapeutic window, is one such dual 
CYP3A4/P-gp substrate shown to interact with GFJ [117]. The increase in cyclosporine AUC 
ranges from 20 to 60%, relative to water or orange juice [47]. To assess whether 
furanocoumarins mediate the cyclosporine-GFJ interaction, a randomized crossover study 
involving 18 healthy volunteers compared the effects of GFJ, a “furanocoumarin-free” GFJ 
(prepared from the GFJ), and orange juice (control) on oral cyclosporine PK [63]. Median dose-
corrected cyclosporine AUC with GFJ was significantly higher (by ~38%) than that with orange 
juice. In contrast, relative to orange juice, furanocoumarin-free GFJ had no consistent effect, 
with a median concentration-time profile that was indistinguishable from that with orange juice. 
Complementary in vitro studies with Caco-2 cell monolayers showed that, relative to vehicle, 
diluted extracts derived from GFJ and orange juice, as well as two purified furanocoumarins 
(bergamottin and 6′,7′-dihydroxybergamottin), partially increased cyclosporine apical-to-
basolateral translocation, whereas the furanocoumarin-free GFJ extract had no effect. These 
observations supported furanocoumarins as candidate P-gp inhibitors in GFJ. Furanocoumarins 
were concluded to mediate, at least partially, the cyclosporine-GFJ interaction in vivo through 
inhibition of enteric CYP3A and possibly enteric P-gp. 
 
Recent studies in rats evaluated potential interactions with the anti-gout agent colchicine and 
antiemetic domperidone, both of which are dual CYP3A/P-gp substrates. The effect of a GFJ 
concentrate on colchicine intestinal permeability was evaluated in Caco-2 cell monolayers and in 
the in situ rat intestinal perfusion model [118]. With Caco-2 cells, at the highest concentration of 
GFJ tested (10%, v/v), colchicine apical-to-basolateral translocation was increased by 75%, and 
basolateral-to-apical translocation was decreased by 45%, relative to control (transport buffer). 
In addition, GFJ (10%, v/v) increased colchicine ileal and jejunal permeability by 2- and 1.5-
fold, respectively, in the in situ perfused intestine. These data were consistent with inhibition of 
enteric P-gp by GFJ. The effect of a commercially available GFJ extract was evaluated on 
domperidone exposure in rats [119]. Domperidone (10 mg/kg) was administered orally, two 
hours after GFJ extract (2 mL/kg). The sum of partial AUCs (0-0.25 h, 0-2 h, 4-8 h) with GFJ 
extract was 16% greater than that with water, albeit the difference was not significant (p>0.05). 
As with cyclosporine, interpretation of the underlying mechanism of the colchicine- and 
domperidone-GFJ interactions is confounded by the dual CYP3A/P-gp nature of these substrates. 
However, unlike cyclosporine, clinical relevance has not been established. 
 
The inconclusive results of studies utilizing dual CYP3A/P-gp substrates could be resolved using 
P-gp substrates that undergo negligible metabolism. Although GFJ has been shown to inhibit 
translocation of such substrates in vitro, observations have not translated to the clinic. For 
example, GFJ had a negligible effect on systemic exposure to digoxin, as evidenced by a <10% 
increase in mean AUC0-24 relative to water [120]. Other minimally metabolized substrates, 
including the antihistamine fexofenadine and the β-blockers talinolol and celiprolol, also have 
been tested. Unexpectedly, healthy volunteer studies showed a significant decrease in mean 
AUC of these three drugs when taken with GFJ, by 13-63% relative to water [59, 121, 122], 
prompting investigations of this newly identified mechanism underlying drug-fruit juice 
interactions (see Uptake Transport Proteins). 
 
Orange Juice. Pravastatin, which undergoes minimal metabolism, is a substrate for P-gp and 
two other apically-located efflux transporters, multi-drug resistance-associated protein 2 (MRP2) 
and breast cancer-resistance protein, as well uptake transporters (organic anion transporting 
polypeptides) [123]. A clinical study involving 14 healthy volunteers given a single dose of 
pravastatin (10 mg) and multiple glasses of commercially available orange juice (reconstituted 
from concentrate) given over 195 min (total volume, 800 mL) showed a 50% increase in mean 
AUC of pravastatin relative to water [124]. The authors speculated upregulation of pravastatin 
absorption in the intestine by orange juice, as a similar study in rats showed an increase in 
intestinal Oatp1 and Oatp2 mRNA and protein expression. Net inhibition of efflux by orange 
juice also may explain this interaction. Naringin and some polymethoxyflavones have been 
shown to inhibit P-gp and MRP2 in vitro and may represent candidate causative ingredients 
[125, 126]. 
 
Uptake Transport Proteins 
Organic anion transporting polypeptides (OATPs) are transmembrane transporters that facilitate 
uptake of a number of endogenous compounds and drugs [127]. These transporters are gaining 
attention as important determinants of drug disposition [128]. The human OATP family consists 
of 11 members, with OATP1A2, OATP1B1, OATP1B3 and OATP2B1 as the most characterized 
[129]. Of these, OATP1A2 and OATP2B1 have been reported to be expressed on apical 
membranes of enterocytes [130]. 
 
Grapefruit Juice. The initial clinical study examining effects of fruit juices, including GFJ, on 
enteric P-gp activity using fexofenadine as a probe substrate showed an unforeseen mean 
decrease in fexofenadine AUC, by 63% relative to water (see Efflux Transport Proteins). Mean 
elimination half-life was unchanged. This atypical interaction was attributed to inhibition of an 
apically located intestinal uptake transporter [59]. Subsequent clinical and in vitro studies 
substantiated GFJ as an inhibitor of enteric OATP activity [131-134]. Reduced exposure could 
lead to reduced effect. Indeed, the package insert for fexofenadine (Allegra®) notes that the size 
of histamine-induced skin wheal and flare was significantly larger when fexofenadine was taken 
with GFJ (or orange juice) than when taken with water [135]. Based on these PK and PD 
outcomes, the manufacturer recommends taking fexofenadine with water. In addition to 
fexofenadine, GFJ has been shown to decrease mean AUC of other OATP substrates, including 
talinolol [121], celiprolol [122], acebutolol [136], etoposide [137], and L-thyroxine [138], by 11 
to 56% relative to water. Only two of these studies (celiprolol and L-thyroxine) assessed PD 
outcomes and reported no effect, albeit in healthy volunteers. Clinical significance for the 
remaining substrates has not been established. Nevertheless, inhibition of enteric OATPs is 
recognized as an additional mechanism of altered drug disposition by GFJ. That is, GFJ can 
decrease, significantly, systemic exposure to OATP substrates, with a consequent potential for 
reduced efficacy. This relatively new type of mechanism is discussed in detail in two recent 
reviews [139, 140]. 
 
OATP1A2 and the flavonoid, naringin, have been proposed as the major transporter and 
causative ingredient involved in the interaction between GFJ and fexofenadine, as well as 
talinolol. In vitro studies with OATP-transfected human epithelial cervical cancer (HeLa) cells 
supported a role for OATP1A2 in uptake of both drugs [59, 61, 141]. One in vitro study assessed 
the uptake activity of several OATPs, and showed OATP1A2 as the only enteric OATP capable 
of taking up fexofenadine [133]. A clinical study investigating the impact of GFJ on intestinal 
transporter expression showed no difference in OATP1A2 protein (and P-gp) expression 
between GFJ and water in duodenal biopsies obtained from healthy volunteers, suggesting GFJ 
may not destroy transport proteins via mechanism-based inhibition [133]. That is, the mechanism 
of inhibition of enteric transporter activity by GFJ may differ from that of enteric CYP3A 
activity. Unlike OATP2B1-transfected HeLa cells, a separate study with OATP2B1-transfected 
human embryonic kidney (HEK) 293 cells demonstrated fexofenadine as a substrate for 
OATP2B1 [142]. GFJ and components (including naringin) have been shown to inhibit uptake of 
the OATP substrate estrone-3-sulfate in OATP2B1-transfected HEK293 cells, by up to 80% 
[134], but additional studies are needed to determine whether GFJ/components inhibit 
OATP2B1-mediated uptake of fexofenadine, as well as to clarify differences in fexofenadine 
uptake between transfected cell lines. 
 
Naringin has been implicated as a major causative enteric OATP inhibitor in GFJ. Healthy 
volunteers (n=12) were given fexofenadine (120 mg) with GFJ (300 mL), an aqueous solution of 
naringin at the same concentration as that in GFJ (1200 μM), or water [61]. Relative to water, 
GFJ and naringin decreased fexofenadine mean AUC by 42% and 22%, respectively. The 
authors concluded that naringin most likely inhibited enteric OATP1A2, resulting in decreased 
fexofenadine bioavailability. The 50% difference in fexofenadine AUC between GFJ and 
naringin suggested other ingredients contribute to the fexofenadine-GFJ interaction. 
 
A recent in vitro study involving the leukotriene receptor antagonist, montelukast, and a clinical 
trial involving the renin-inhibiting antihypertensive agent, aliskiren, added two potential drugs to 
the growing list of enteric OATP-mediated drug-GFJ interactions [143, 71]. In vitro studies with 
Caco-2 cells and OATP2B1-transfected Madin-Darby canine kidney cells demonstrated that 
montelukast undergoes carrier-mediated transport by OATP2B1. GFJ at 5% and 10% (v/v), and 
orange juice at 10%, reduced montelukast permeability significantly (p<0.05), by ~30% relative 
to control (buffer). Clinical relevance of these interactions has not been examined. Aliskiren is a 
substrate for OATP2B1, as well as CYP3A and P-gp. Healthy volunteers (n = 11) were 
administered single-strength GFJ (200 mL) three times daily for 5 days, and aliskiren (150 mg) 
was given on the third day. Relative to water, GFJ significantly reduced mean aliskiren AUC and 
Cmax, by 61% and 81%, respectively. Mean elimination half-life remained essentially unchanged. 
Net inhibition of enteric OATP-mediated uptake by GFJ could account for the reduced exposure. 
Other potential mechanisms included a physicochemical interaction between GFJ and aliskiren 
or an alteration of physiologic conditions in the gut by GFJ. Follow-up in vitro and clinical 
studies are needed to clarify the role of OATP in the aliskiren-GFJ interaction, as well as effect 
on PD outcomes. 
Orange Juice. Orange juice contains trace amounts of furanocoumarins and has minimal enteric 
CYP3A inhibitory effect [126, 144]. As such, orange juice has been used as a control juice, 
rather than water, in some clinical studies. However, orange juice has been shown to reduce 
systemic exposure, significantly (by 22-83%), to fexofenadine [59], atenolol [145], and 
celiprolol [146]. Decreased mean AUC (up to 38%) also has been observed for the 
fluoroquinolones ciprofloxacin [147] and levofloxacin [148] with calcium-fortified and non-
fortified orange juice. Any or all of these interactions could involve inhibition of enteric OATP 
by orange juice, as fexofenadine, levofloxacin, and celiprolol, have been shown to be substrates 
for OATP in vitro [59, 149, 150]. 
 
Hesperidin, a major component of orange juice, is a flavonoid glycoside with a molecular 
structure similar to that of naringin [151]. Hesperidin has been shown to inhibit OATP1A2-
mediated uptake of fexofenadine in vitro, with an IC50 of 2.7 μM [61], similar to that of naringin 
(3.6 μM). However, hesperidin produced only 60% maximum inhibition at the highest tested 
concentration (100 μM). A study in rats duodenally administered celiprolol (5 mg/kg) and orange 
juice or aqueous solution of hesperidin (208 μg/mL or 340 μM, the same concentration as that in 
the orange juice) showed a mean AUC decrease of 75% and 78%, respectively, relative to water. 
The AUC in the hesperidin group was not significantly different than that of the orange juice 
group, suggesting hesperidin contributes to the celiprolol-orange juice interaction. Studies with 
other OATP substrates would clarify the in vivo significance of hesperidin. 
 
Pomelo Juice. The previously mentioned clinical study of six healthy male volunteers showed a 
significant decrease (by ~60%) in mean AUC and Cmax of sildenafil after ingestion of a 240-mL 
glass of fresh-squeezed pomelo juice [77] (see Cytochrome P450 3A). One possible explanation 
was inhibition of intestinal uptake (e.g., by OATP) of sildenafil by the juice. No follow-up 
studies examining sildenafil as an OATP substrate have been reported. 
 
Apple Juice. The effect of apple juice on fexofenadine uptake also was evaluated in the initial 
fexofenadine-GFJ interaction study [59]. The OATP-mediated uptake of [14C]fexofenadine was 
examined in the presence and absence of increasing concentrations (0-5%, v/v) of apple juice in 
OATP1A2-transfected HeLa cells. The highest concentration of juice inhibited activity by >85% 
relative to water. Clinical study results also were significant, as apple juice decreased mean AUC 
of fexofenadine by ~70% compared to water. To the authors’ knowledge, no follow-up in vitro 
and clinical studies involving apple juice per se have been published. However, a recent in vitro 
study investigated the effect of three flavonoids (apigenin, kaempferol, quercetin) on OATP 
activity in OATP1A2- and OATP2B1-transfected HEK293 cells using fexofenadine and 
bromosulfophthalein as substrates [152]. Quercetin, known to be present in apples (Malus 
domestica) and apple juice [153], inhibited OATP1A2-mediated fexofenadine uptake, with an 
IC50 of 13 μM. Quercetin also inhibited OATP1A2- and OATP2B1-mediated 
bromosulfophthalein uptake, with Ki values of 22 and 8.7 μM, respectively. Further studies are 
needed to determine if quercetin is a major causative ingredient in apple juice in vivo. 
 
DISCORDANCE BETWEEN IN VITRO AND CLINICAL STUDIES 
Although a number of fruit juices have been shown to inhibit several intestinal CYPs and 
transporters in vitro, some of the interactions have not translated to the clinic. Fruit juices clearly 
inhibit intestinal metabolism and transport, but the magnitude of change in Cmax and/or AUC 
often is insignificant, unpredictable, and highly variable, which cannot be explained adequately. 
These in vitro-in vivo discordances may be due to a lack of sufficient information to determine a 
positive interaction. A deficiency common to most drug-fruit juice interaction studies is a limited 
or non-existent chemical description of the juice. Although several reasons account for 
discrepancies between in vitro and clinical studies [24, 154], one explanation is that the 
concentration of inhibitors in the juice might not be sufficient to inhibit metabolism/transport in 
vivo. The sources and complexity of a plant’s chemical constituents are underappreciated. 
Concentrations of bioactive compounds in a natural food product vary depending on ecological 
conditions, manufacturing process, storage conditions, and a host of other environmental factors 
[155]. Thus, testing a random juice product in vitro and in vivo without understanding the 
chemical makeup provides no basis for comparison between studies. One of the most 
fundamental solutions to establishing meaningful physiological dose-response relationships for 
dietary substances is to characterize the product prior to use. 
 
Few in vivo drug-fruit juice interaction studies reported concentrations of bioactive constituents 
in the clinical test juice. Since the establishment of furanocoumarins as unequivocal mediators of 
enteric CYP3A-based interactions in 2006 [53], only a handful of clinical studies involving 
CYP3A substrates reported furanocoumarin content in the test juice (Table 2). Furanocoumarins 
have been studied to the extent that they can be considered ‘marker’ compounds, defined as 
compounds unique to a dietary substance [156]. Characterization of a given juice in terms of 
furanocoumarin content could be used to predict the likelihood and magnitude of an interaction. 
For example, likelihood of an interaction can be predicted by the presence of furanocoumarins, 
and effect size can be correlated to the amount of marker compound(s). Between-study 
comparisons also can be made. Indeed, 6′7′-dihydroxybergamottin was used in a recent PK 
modeling study investigating the impact of CYP3A-based inhibition on drug disposition [157]. 
In addition to grapefruit and related citrus juices, furanocoumarins are present in substantial 
amounts in umbelliferous vegetables (e.g., parsnips, celery, parsley) and are not destroyed by 
normal cooking procedures [158]. Furanocoumarins also are present in Kampo extract 
medicines, which originated in Japan and are used widely in Asia [159]. A similar strategy could 
be applied to predict likelihood and magnitude of interactions between these foods/natural 
medicines and traditional medications. 
 
APPLICATIONS: NEW TWISTS ON OLD INTERACTIONS 
Mechanisms and causative ingredients underlying enteric CYP3A inhibition by GFJ have been 
studied for more than two decades [160]. The information gained has been used by different 
groups to their advantage. For example, the potential for GFJ to increase systemic drug 
concentrations, and consequent PD effect, of certain opiates is a widely discussed topic among 
recreational users in online forums [161, 162]. The scientific community also has attempted to 
exploit enteric CYP3A inhibition for pharmacoeconomic and therapeutic purposes. Intentional 
manipulation of enteric CYP3A by GFJ and individual components is of particular interest in the 
cancer treatment and organ transplantation areas [137, 163-166]. For example, inhibition of 
enteric CYP3A by GFJ could improve oral bioavailability of some agents without GFJ exerting 
additional adverse effects. In addition, the cost and side effect severity of these multi-drug and 
toxic regimens could be reduced through dose and/or dosing frequency reduction by 
coadministration with GFJ, possibly improving adherence. However, several drugs in these 
therapeutic classes have a narrow therapeutic range and require close monitoring. Without 
thorough characterization of the juice product, these practices are at best ineffective, and at 
worst, place the patient at risk for unfavorable outcomes. 
 
Table 2: Clinical drug-citrus juice interaction studies in which candidate causative ingredients in 
the test juice were quantified 
Juice Drug Tested Confirmed or Suspected Active Constituent 
Constituent Concentration 
in Test Juice(s) 
(μM) 
Reference 
Grapefruit Fexofenadine Naringin 1200 [61] 
 Cyclosporine GFJ/FC-free GFJ/OJ* 11.5/0.08/ND [63] 
  DHB 9.5/0.03/ND  
  BG 149/104/ND  
  Narirutin 440/331/ND  
  Naringin 8/5/ND  
  Hesperidin 15/8/ND  
  Neohesperidin 15/2/ND  
  Didymin 30/9/ND  
  Poncirin 0.56/0.01/7.66  
  Nobiletin 0.15/0.02/1.95  
  Tangeretin   
 Dextromethorphan DHB 37 [64] 
  BG 27  
  Naringin 850  
  Naringenin 0.82  
 Sunitinib DHB 2.7, 5.7†  
  BG 33, 24† [69] 
Pomelo Felodipine Guanximiyou/Changshanhuyou§  [76] 
  DHB 1.3/ND  
  BG 8.2/ND  
  Paradisin A 1/ND  
  Paradisin B 0.1/ND  
  Paradisin C 3.5/ND  
*Units are ppm 
†A second lot of the same brand was used for the last two patients due to expiration date. 
§Two varieties of pomelo fruit 
DHB, 6′,7′-dihydroxybergamottin; BG, bergamottin; FC, furanocoumarin; OJ, orange juice; NS, not significant; ND, not detected 
 
An in vivo study of wild-type and humanized CYP3A4 transgenic mice orally administered the 
anticancer agent, erlotinib, and BAS 100, a spiro-ortho-ester mechanism-based CYP3A4 
inhibitor isolated from GFJ, demonstrated a 2.1-fold increase in erlotinib AUC, relative to 
control (saline) [163]. Results illustrated the potential of BAS 100 to “boost” systemic drug 
exposure, and decrease associated variability, of erlotinib in cancer patients. The erlotinib study 
is one of the first attempts to test the strategy of deliberate inhibition of intestinal first-pass 
metabolism. 
 
A clinical trial investigating the effect of GFJ on sirolimus PK in advanced solid tumor patients 
is ongoing [167]. Initial results showed no effect, possibly due to insufficient furanocoumarin 
content in the GFJ product selected [168]. This approach is unsettling because GFJ was chosen 
as a ‘boosting’ agent for a narrow therapeutic index drug but was not characterized before 
administration. A more ‘potent’ GFJ containing inhibitory concentrations of furanocoumarins 
(not reported) given subsequently to the subjects significantly increased plasma concentrations of 
sirolimus, by up to 400% relative to water [164]. A daily glass of GFJ (240 mL) was projected to 
lower sirolimus costs by 50% [169]. The same investigators have suggested ‘GFJ boosting’ to 
reduce dose and cost for the tyrosine kinase inhibitor, lapatinib [165]. One 250-mg lapatinib 
tablet, accompanied by food and/or GFJ, was speculated to increase systemic exposure 
comparable to that of five 250-mg tablets on an empty stomach, resulting in a total cost savings 
of 80%. 
 
The strategy of using GFJ to lower drug costs also has been considered in the management of 
immunosuppression. Approximately 20 years ago, it was proposed that a compound which 
inhibits pre-systemic metabolism of cyclosporine without causing systemic effects could have 
clinical value [170, 171]. GFJ would seem an ideal candidate since it has been shown to increase 
cyclosporine exposure [172]. However, the efficacy and pharmacoeconomic impact of 
combining cyclosporine and GFJ have not been determined. A prospective clinical study 
evaluated the effect of two commercially available GFJ products on tacrolimus PK in liver 
transplant recipients [173]. After administration of GFJ (250 mL twice daily) for one week, mean 
trough tacrolimus concentration was enhanced significantly, by ~10 ng/mL compared to 
baseline. The dose of tacrolimus was decreased by ~2 mg per day, which amounted to a savings 
in drug costs of ~$9 per day. The safety and pharmacoeconomic benefit of a GFJ boosting 
strategy have not been evaluated sufficiently to change disease management. As with the anti-
cancer agents, promising conclusions are unwarranted due to insufficient data on the PK-PD 
relationship between the causative ingredients in GFJ (e.g., furanocoumarins) and tacrolimus, as 
well as the large interindividual variability in response, making therapeutic outcomes virtually 
unpredictable. 
 
It seems tempting to take advantage of the effects of a natural product like GFJ to boost systemic 
drug exposure and decrease inter-/intraindividual variability in PK, and ideally PD, outcomes. 
The dose and dosing schedule of certain drugs could be reduced to lower drug costs and improve 
patient compliance. However, further research is required on the mechanisms of action, causative 
ingredients, and PK-PD relationship with respect to individual juice components and the drug of 
interest. Given the possibility of using GFJ and/or individual constituents as a ‘drug-sparing 
agent,’ a standardized approach to investigating interaction potential is imperative. Early 
evaluation of CYP and transporter inhibition properties of new chemical entities is routine during 
drug development. A similar approach could be adopted for dietary substances. However, 
information providing a systematic approach for the study, prediction, and management of drug-
dietary substance interactions is lacking. Ideal management approaches would be those 
developed based on well-designed in vitro studies. Information gained from rigorous in vitro 
studies, combined with that gained from in silico methods, could optimize clinical study design 
and clarify the clinical significance of an interaction. Robust PK/PD models could then be used 
to determine potential risks of long-term inhibition of intestinal metabolism/transport by a given 
dietary substance on pharmacotherapeutic outcomes. 
 
CONSIDERATIONS FOR IMPROVED RESEARCH PRACTICES 
Dietary substances in the United States, which include supplements/herbal 
remedies/nutraceuticals, are regulated under the same framework as foods, separate from the 
regulation of drugs. Individuals representing multiple sectors (science, clinical practice, public) 
have argued both for and against this policy, which is unlikely to change in the foreseeable 
future. As such, it is unrealistic to expect the U.S. Food and Drug Administration (FDA) to 
require high-quality scientific evidence from the relevant industries [174]. It also is unlikely that 
the FDA will require more extensive drug-dietary substance interaction studies other than those 
recommended. However, legislation need not be passed to undertake sound scientific research. 
Several approaches can be adopted for rigorous evaluation of potential drug-dietary substance 
interactions. Practices regarding peer review of the drug interaction liability of a dietary 
substance should be the same as those for a drug, particularly with respect to reproducibility. If 
the dietary substance is not described in detail, then other investigators will be unable to 
reproduce one or more facets of the study. 
 
Since dietary substances contain multiple, often unknown, bioactive ingredients that vary in 
composition between batches and manufacturers, characterization of causative ingredients and 
mechanisms of action is essential. Identification of components responsible for these interactions 
can be challenging. Generally, biologic action is not determined by a single active compound. A 
set of ‘marker’ compounds that can be applied for definitive authentication of the test material 
would serve as an indicator of quality and potency. The selected markers should be unique to the 
selected species and represent health-relevant principles [156]. The identity of constituent(s) 
should be confirmed initially by in vitro methods that screen for potential interactions. Such 
experiments provide mechanistic information about inhibitory capacities, as well as specific 
enzymes and/or transporters involved. 
 
Reporting of the characterization of dietary substances used in clinical trials must be improved. 
Many clinical studies lack basic information about the test material. Considering the 
requirements for a drug investigated clinically, the disconnect becomes obvious. A substance 
derived from a “natural source” does not imply that the rigors of reproducibility should be 
abandoned. At minimum, for commercially available products, the brand name, manufacturer, lot 
number, ingredients, preparation directions, manufacturing process, and origins of growth and 
production should be stated. For freshly prepared test material, scientific name, quantity, plant 
part used, site of collection, preparation procedures, and storage conditions should be 
documented [175-177]. If a marker compound has been identified or suspected, quantitative 
analysis by analytical chemistry techniques should be conducted to determine the presence 
and/or quantities of relevant constituents. Since administration of ‘standardized’ fruit juices is 
not possible, it would be more realistic to quantify a particular known/suspected component, or 
group of components, prior to use. This practice would enable some degree of between-study 
comparison. 
 
Stringent methods for evaluating potential drug-dietary substance interactions are critical as new 
products enter the market. However, the aforementioned tasks do not rely solely on one 
discipline. Rigorous investigations of complex botanical products require collaboration from 
many areas, including clinical pharmacology, pharmacognosy/natural products chemistry, and 
botany [178]. Specific botanical expertise, combined with knowledge of appropriate assays and 
other experimental tools for testing compounds, would improve greatly the deficiency in the 
characterization of natural products used in clinical trials. A multidisciplinary, translational 
research approach is necessary to explain fully these relatively unexplored types of drug 
interactions. 
 
SUMMARY AND PERSPECTIVE 
Interactions between medications and dietary substances, as foods or supplements, remain a 
relatively understudied, likely underreported, and generally misunderstood area of 
pharmacotherapy. Growing impatience over the slow introduction of innovative drugs on the 
market, combined with rising health care costs, has contributed to the ever-increasing obsession 
by consumers with quick-fix, “all-natural” remedies. Concurrent with the increasing use of 
dietary supplements and so-called ‘superfoods’, including fruit juices, is the upward trend of 
polypharmacy, all hindering optimal therapeutic outcomes. Discovery of the effect of GFJ on 
felodipine PK and PD launched renewed interest in the study of drug-dietary substance 
interactions. Although inhibition of enteric CYP3A has been studied extensively, questions still 
remain. Additional mechanisms involving inhibition of enteric active uptake transporters have 
been identified. In vitro studies have added to the list of drugs that may interact with dietary 
substances in vivo, but well-designed, proof-of-concept clinical studies are limited. Numerous 
other potential drug-dietary interactions are anticipated to emerge as new supplements and 
different types of foods (e.g., organic, functional, genetically modified, fortified) are created. The 
complexity of dietary substances and lack of adequate characterization preclude between-study 
comparisons, as well as accurate predictions of drug interaction liability. Ongoing challenges 
involve systematic investigations of underlying mechanisms, causative ingredients, and PK-PD 
relationships with respect to individual juice components and drugs of interest. The ultimate goal 
is to develop common practice guidelines to provide a consistent approach in managing drug-
dietary substance interactions appropriately. 
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ABBREVIATIONS 
DDIs drug-drug interactions 
  PK pharmacokinetics 
  PD pharmacodynamics 
  CYP cytochrome P450 
  GFJ grapefruit juice 
  AUC area under the curve 
  FC furanocoumarin 
  MOM 3-methoxymorphinan 
  ER extended release 
  tid three times daily 
  d days 
  NSP not specified 
  bid two times daily 
  qd daily 
  Cmax maximum concentration 
  NS not significant 
  CBJ cranberry juice 
  UTI urinary tract infection 
  P-gp P-glycoprotein 
  INR International Normalized Ratio 
  PNPA p-nitrophenylacetate 
  IC50 half maximal inhibitory concentration 
  SULTs sulfotransferases 
  
MRP2 multi-drug resistance-associated 
protein 2 
  OATPs organic anion transporting 
polypeptides 
  HEK human embryonic kidney 
  Ki inhibition constant 
  DHB 6′,7′-dihydroxybergamottin 
  BG bergamottin 
  FC furanocoumarin 
  OJ orange juice 
  ND not detected 
  FDA Food and Drug Administration 
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